Mar 31, 2018
1.1 Total Cost of Quoted investment is Rs. 4005.53lacs (Market Value Rs. 5443.34/-lacs) as on 31.03.18
1.2 investments are valued at fair value on the basis of book value as per the last audited annual accounts of investee Companies available with the company i.e for the year ending 31.03.2017.
1.3 The shares of ind Swift Laboratories Ltd are pledged to Banks as per the sanctioned Corporate Debts Restructuring Scheme of ind Swift Laboratories Ltd.
1.4 Essix Biosciences Ltd, Fortune India Construction Ltd and Mansa Print & Publishers Pvt Ltd are Related Parties
2.1 Fixed Deposits with banks are Rs.91.14lacs (Previous Year Rs. 46.56lacs) are Pledged as margin money with banks against issue of Bank Gurantees.
2.2 Balance with Banks includes Balance on account of unpaid dividend of Rs. 2.93lacs(Previous Year Rs. 5.66lacs)
2.3 During the period the Company has Transferred a sum of Rs. 2.73lacs to investor Education and Protection Fund on account of Unclaimed dividend for Financial Year 2009-10 (Previous Year Rs. 2.67lacs)
3.1 in the opinion of the Board, the current assets,loans & advances shown in the Balance Sheet have a value of realization in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet and provision for all known and determined liabilities is adequate.
3.2 Advances recoverable includes advances to suppliers and advances to staff and other advances.
4.1 Term Loan from Banks & Financial Institutions are secured by way of first pari-passu charge over entire fixed assets of the company, second pari-passu charge over the entire current assets of the company, personal guarantee of Directors and by way of pledge of shares of promoters. Restructured Bill Discounting/Factoring facilities are secured by way of subservient charge over entire current assets of the company.
4.2 Since the Company is unable to repay the installments and Banks have exited from the CDR mechanism, the installments due and falling due in next twelve months have not been segregated as current liability. The entire loan amount has been shown as long term liability except loan accounts which are being repaid as per repayment schedule.
5.1 Company has provided remuneration to Directors in excess of the limits prescribed in schedule V of Companies Act, 2013.However Company is in process of obtaining the approval from Central Government in this regard as required in schedule V of Companies Act, 2013
6. Contingent liabilities outstanding as on 31.03.2018 are as under:
a) Foreign Letter of Credit/inland Letter of Credit/Bank Guarantee issued by Bankers:
b) Arrears of Cumulative Dividend on cumulative Redeemable Preference Shares amounting to Rs. 99.40 Lacs Previous year (85.20Lacs).
c) In respect of income Tax matters pending before appellate authorities/Tribunal/High Courts which the Company expects to succeed, based on decisions of Tribunals/Courts there is contingent liability amounting to Rs.576.16 Lacs.
d) In respect of Sale Tax matters pending before appellate authorities/Tribunal/High Courts which the Company expects to succeed, based on decisions of Tribunals/Courts there is contingent liability amounting to Rs.1069.96Lacs.
e) In respect of Service Tax matters pending before appellate authorities/Tribunal which the Company expects to succeed, based on decisions of Tribunals/Courts. There is contingent liability amounting to Rs.260.61 Lacs.
f) In respect of Central Excise matters pending before appellate authorities/Tribunal which the Company expects to succeed, based on decisions of Tribunals/Courts. There is contingent liability amounting to Rs.1473.82 Lacs.
7. Provision for Doubtful debt amounting to Rs. 3742.66 Lacs has been made by the company during the year, being considered doubtful of recovery, as per company''s policy and has been shown under the head exceptional items.
8. Loss for the year has increased by Rs. 592.81 lacs being the stocks written off by the company on account of expired/ spoilage of stocks of raw material which was identified by the management during the financial year, being not realizable in normal course of business.
9. Post applicability of Goods and Service Tax (GST) w.e.f 1st July 2017, Revenue from operations are disclosed net of GST. Accordingly the revenue from operations and Excise Duty expenses for the year ended 31.03.2018 are not comparable with previous periods.
10. R & D: Company is consistently undertaking Research & Development in new areas of Medicine. The R & D facility of the company is duly recognized by Deptt. of Science & Technology, Govt. of India. Company''s team consisting of highly qualified scientists has proven their expertise in various areas of technology development. Expenses on Research phase are charged to Profit and Loss account. as laid by Ind AS 38 issued by institute of Chartered Accountant of India on Intangible Assets. Expenditure on R&D incurred by the Company during the Year is:
The Depreciation/Amortisation related to Research & development are clubbed under respective heads in profit & loss account.
11. Segment Reporting
Primary Segment (Business Segments)
The Company operates mainly in the business segment of Pharmaceutical Products, and in the opinion of the management the inherent nature of activities in which it is engaged are governed by the same set of risks and reward.
12. (i) The Company has provided Rs. 324.06lacs as provision towards the company''s gratuity policies maintained with LiC as per valuation by the LiC.
(ii) Provision for Leave Encashment has been made as per the rules of the Company without actuarial valuation.
13. (i) The fixed deposits of the company has been restructured by the Company Law Board vide its order dated 30.09.2013 in view of petition CP No, 27.02.2013 filed by the company. As per the scheme approved by the Company Law Board the fixed deposits are now repayable over a period of one to five years from the date of maturity. The effect of reschedulement of fixed deposits has been incorporated in Balance Sheet as per the approved scheme. However the company has again filed application with National Company Law Tribunal (NCLT) to again restructure the repayment schedule of fixed deposits as the company is finding it difficult to make the repayment due to liquidity problem. However NCLT vide its order dated 08.12.17 directed the company to repay its fixed deposits as per original Company Law Board order dated 30.09.2013. However the Company filed appeal against the said order with National Company Law Appellate Tribunal (NCLAT) and the matter is subjudice with NCLAT.
(ii) Interest Accrued on fixed deposit during the year for Rs.227.99 lacs has not been provided in accounts as the same is payable to fixed deposit holders at the time of maturity of fixed deposits as per the scheme approved by Company Law Board as mentioned above.
(iii) interest Excess Provided on Fixed Deposit in earlier Years for Rs. 269.32Lacs has been written Back during the year.
14. In view of the financial crisis being faced by the company, Company is finding difficulties in making payment of dues to the banks/financial institutions. Hence, accounts pertaining to Cash Credit (CC), Term Loans (TL), Working Capital Term Loans (WCTL), Funded interest Term Loans (FITL) with the banks have been declared as NPAs by respective banks due to nonpayment of dues on time. Some of the banks have not charged interest on CC,TL, WCTL & FITL accounts post such accounts becoming NPAs. The accrued liability on account of the same amounting to Rs. 153.63 Crore. (Previous Year 134.76 Crore) has not been provided in the books of accounts.
15.1 Following banks have assigned their debts to Assets Reconstruction Company:
16. IFCI Factors Ltd has vide its letter dated 13.04.2018 approved the one time settlement of due payable by the company for Rs. 6.00 Crore repayable in installment during the year 2018-19 against the outstanding of Rs. 1258.19 lacs as per books of account of the company (Principal Rs. 1050 Lacs in term Rs. 208.19 Lacs). The waiver on account of Principal and Interest for Rs. 658.19 Lacs have been accounted for as income under the head exceptional item in Profit & Loss account for the year ending March 2018.
17. Some of the Banks/ Asset Reconstruction Companies have not provided statements of account of the company. The Balance of Such Banks/Asset Reconstruction Company have been accounted for as per the balance available in the books of accounts of the company and these balances are subject to reconciliation.
18. Since the company is incurring losses and there is no virtual certainty regarding availability of any future taxable profits in coming financial years, as such in accordance with Ind AS12 (Income Tax) the company has not recognized deferred tax asset.
19. During the year the company has paid Rs. 239.50 Lacs to the Executive Directors as advance which is recoverable/to be settled against the remuneration for the financial year 2017-18 as and when the remuneration is approved by the Central Govt.
20. Advance to KMP include Rs. 816.76 lacs (P/Y 596.26Lacs) due from directors of the company. Maximum balance outstanding during the year is Rs 835.76 lacs (P/Y 596.26Lacs).
21 (i). The operations of Dairy unit of the Company were discontinued in the year 2013-14. Since there are no operation in Dairy unit, impairment loss in respect of Capital Work in Progress of Dairy unit for Rs. 93.93 lacs has been provided in accounts.
(ii). Due to Suspension of activities at Unit i, and ii at Parwanoo (H.P.) since March 2014, There are indication which suggest impairment as per Ind AS-36 issued by ICAI in the value of fixed assets being plant & machinery and other fixed assets of the Company. The management is in the process of getting an impairment study done and this financial impact of the impairment loss, if any, will be accounted for at the material time, when the impairment study will be completed.
22. Balance of Debtors, Creditors and Loan & Advances are subject to Confirmation.
23. Remittance in Foreign Currency on Account of Dividend:
No Remittance in Foreign Currency on account of dividend was made during the year 2017-18.
24. Earning Per Share (EPS)
(a) Basic EPS
25. The previous year figures have been re-arranged and re-grouped wherever found necessary.
26. Related Party Disclosure
(a) List of related parties & their relationship - As per annexure- ''A''
(b) Related party transactions. - As per annexure- ''B''
Mar 31, 2015
1. The Prefrence Shares shall rank for dividends in priority to equity
Shares for time being. These shares shall be entitled to rank in
priority to equity shares as regards repayment of Capital and arrears
of dividend declared, but shall not be entitled to any further
participation in profit or assets of the Company.
2. Term Loan from Banks & Financial Institutions are secured by way of
first pari-passu charge over entire fixed assets of the company,second
pari-passu charge over the entire current assets of the
company,personal guarantee of Directors and by way of pledge of shares
of promoters. Restructured Bill Discounting/Factoring facilities are
secured by way of subservient charge over entire current assets of the
company. Vehicles loans are secured by way of hypothecation of vehicles
financed.
3.regarding regd. under The Micro Small and Medium Enterprises
Development act 2006. Hence, the information required to be given in
accordance with Section 22 of the said act is not ascertainable and not
disclosed.
4. Total Cost of Quoted Investment is Rs. 4005.53 lacs(Market Value
Rs.3016.16lacs) and Unquoted Investment is Rs. 506.80 lacs
5. The shares of Ind Swift Laboratories Ltd are pledged to Banks as
per the sanctioned Corporate Debts Restructuring Scheme of Ind Swift
Laboratories Ltd.
6. Ind Swift Laboratories Ltd, Essix Biosciences Ltd, Fortune India
Construction Ltd and Mansa Print & Publishers Pvt. Ltd are Associates.
7. Fixed Deposits with banks are Rs.43.17 lacs (P/Y Rs. 225.73 lacs)
out of which Rs. 43.11 lacs (P/Y Rs. 225.53 lacs) are Pledged as margin
money with banks.
8. Balance with Banks includes Balance on account of unpaid dividend
of Rs. 12.98 lacs(P/Y Rs. 17.56 lacs)
9. During the period the Company has Transferred a sum of Rs. 4.58
lacs to Investor Education and Protection Fund on account of Unclaimed
dividend for Financial Year 2006-07 (P/Y Rs. 3.26 lacs)
10. In the opinion of the Board, the current assets,loans & advances
shown in the Balance Sheet have a value of realization in the ordinary
course of business at least equal to the amount at which they are
stated in the balance sheet and provision for all known and determined
liabilities is adequate.
11. Expenses includes Rs.142.76lacs- (P/Y Rs. 36.96lacs) as expenses
relating to previous years.
12. In view of losses, the managerial remuneration paid/provided is in
excess of limit prescribed main schedule V of Companies Act 2013.
However Company is in process of obtaining the approval from Central
Government in this regard.
13. The previous year figures have been re-arranged and re-grouped
wherever found necessary.
14. Contingent liabilities outstanding as on 31.03.2015 are as under:
a) Foreign Letter of Credit/Inland Letter of Credit/Bank Guarantee
issued by Bankers:
(Rs.in Lacs)
Particulars 2014-15 2013-14
FLC /ILC 9.40 1630.91
BG 106.60 18.06
b) Arrears of Cumulative Dividend on cumulative Redeemable Preference
Shares amounting to Rs. 56.80 Lacs Previous year (42.60Lacs).
c) In respect of Income Tax matters pending before appellate
authorities/CIT (Appeals) which the Company expects to succeed, based
on decisions of Tribunals/Courts. There is contingent liability
amounting to Rs.578Lacs.
d) In respect of Sale Tax matters pending before appellate
authorities/CIT (Appeals) which the Company expects to succeed, based
on decisions of Tribunals/Courts. There is contingent liability
amounting to Rs.590.64Lacs.
15. During the year the Company has changed the depreciation policy
from straight line method to Useful Life method of depreciation as
prescribed in Schedule II of the Companies Act, 2013. Due to this
change in the method of depreciation, the reported period
of depreciation is higher by Rs. 1252.66 lacs. However depreciation on
fixed assets whose useful life is already exhausted as on 01.04.2014
amounting to Rs. 335.26 lacs has been debited to General Reserve
Account. The Corresponding Deferred Tax Liability on such fixed assets
amounting to Rs. 63.88 lacs has also been reversed and credited to
General Reserve Account.
16. Trade Receivables include a sum of Rs. 63.39 Cr. Which is
outstanding for a period of more than 3 years and are doubtful of
recovery. However, no provision against the same has been made in the
books of account as the management is hopeful of recovery of the same
through constant follow up or by legal process as the management is
contemplating to initiate legal action against such debtors.
17. Loss for the year has increased by Rs. 2238.75 lacs being the
stocks written off by the company on account of expired/spoilage stocks
of finished goods/raw material which was identified by the management
during the financial year, being not realizable in normal course of
business.
Further, the management has also identified stocks of finished
goods/raw material worth Rs 39.44 Cr. as slow moving/non moving stocks
which has not been written off during the financial year. However the
value of such stock has been taken at realizable value.
18. At the end of the financial year the accumulated losses of the
company are in excess of fifty percent of its net worth. During the
financial year the company has also incurred cash losses.
19. R & D: Company is consistently undertaking Research & Development
in new areas of Medicine. The R & D facility of the company is duly
recognized by Deptt. of Science & Technology, Govt. of India. Company's
team consisting of highly qualified scientists has proven their
expertise in various areas of technology development. Expenses on
Research phase are charged to Profit and Loss account and Expenses
relating to development phase is recognised as an Intangible Asset only
if it meets the recognition criteria as laid by AS 26 issued by
institute of Chartered Accountant of India on Intangible Assets. These
assets are amortised over the useful period of life starting from the
year when the asset first meets the recognition criteria. Expenditure
on R&D incurred by the Company during the Year is:
20. Segment Reporting
Primary Segment (Business Segments)
The Company operates mainly in the business segment of Pharmaceutical
Products, and in the opinion of the management the inherent nature of
activities in which it is engaged are governed by the same set of risks
and reward. The Company has closed its operation in Dairy Division in
the year 2013-14
21. The debts of the company including interest have been restructured
by the corporate debt restructuring cell w.e.f 01.07.2012 under the
aegis of Corporate Debt Restructuring Scheme. As per the approved
scheme, restructured debts are now repayable over a period of eight and
half years including moratorium period of 1-2years. The Debt
Restructuring Scheme is not approved by Non CDR member Tata Capital
Financial Services Ltd. However effect of reschedulement of loan has
been incorporated in Balance Sheet as per corporate debt restructuring
scheme except in case of Tata Capital Financial Services Ltd which has
been taken as per their original sanctioned letter.
22. The fixed deposits of the company has been restructured by the
Company Law Board vide its order dated 30.09.2013 in view of petition
CP No, 27.02.2013 filed by the company. As per the scheme approved by
the Company Law Board the fixed deposits are now repayable over a
period of one to five years from the date of maturity. The effect of
rechedulement of fixed deposits has been incorporated in Balance Sheet
as per the approved scheme.
23. In view of the financial crisis being faced by the company, Company
is finding difficulties in making payment of dues to the banks/
financial institutions i.e. interest and installments in terms of the
CDR package approved by CDR EG vide letter dated 27.12.2012 Hence,
accounts pertaining to Cash Credit (CC), Term Loans (TL), Working
Capital Term Loans (WCTL), Funded Interest Term Loans (FITL) with some
banks have been declared as NPAs by respective banks due to non-payment
of dues on time. Such banks have not charged interest on CC,TL, WCTL &
FITL accounts post such accounts becoming NPAs. The accrued liability
on account of the same amounting to Rs. 85.48 Cr. (Previous Year 37.10
Cr.) has not been provided in the books of accounts.
24. Since the Company is incurring losses and there is no virtual
certainty regarding availability of any future taxable profits in
coming financial years, as such in accordance with AS-22 (Accounting
for Taxes) the Company has not recognized Deferred Tax Asset .
25. Due to Suspension of activities at Unit I, and II since March 2014
and suspension of activity at Dairy Unit since Aug.2013, There are
indication which suggest impairment as per AS-28 issued by ICAI in the
value of fixed assets being plant & machinery and other fixed assets of
the Company. The management is in the process of getting an impairment
study done and this financial impact of the impairment loss, if any,
will be accounted for at the material time, when the impairment study
will be completed.
26. Balance of Debtors,Creditors and Loan & Advances are subject to
Confirmation.
27. Related Party Disclosure
(a) List of related parties & their relationship - As per annexure- 'A'
(b) Related party transactions. - As per annexure- 'B'
RELATED PARTY DISCLOSURES Annexure - '43 A'
LIST OF RELATED PARTIES AND RELATIONSHIPS
(A) ASSOCIATES
1. ESSIX BIOSCIENCES LIMITED.
2. IND SWIFT LABORATORIES LIMITED.
3. MANSA PRINT & PUBLISHERS LIMITED.
4. FORTUNE INDIA CONSTRUCTION LIMITED.
5 DASHMESH MEDICARE PVT LIMITED.
6. 3M ADVERTISING & PUBLISHERS LIMITED.
7. SWIFT FUNDAMENTAL RESEARCH & EDUCATION SOCIETY.
8. HALCYON LIFE SCIENCES PVT. LIMITED.
9. PUNJAB RENEWABLE ENERGY PVT LIMITED.
10. B. M. COSMED PVT. LIMITED.
11. HAKIM FARAYAND CHEMI CO. (IRAN)
12. AKJ PORTFOLIOS PVT. LIMITED.
13. NRM PORTFOLIOS PVT LIMITED.
14. SRM PORTFOLIOS PVT LIMITED.
15. GM PORTFOLIOS PVT LIMITED.
16. VRM PORTFOLIOS PVT LIMITED.
17. VKM PORTPOLIOS PVT LIMITED.
(B) KEY MANAGEMENT PERSONNEL
1. MR. S.R. MEHTA, CHAIRMAN DIRECTORS
2. DR. G. MUNJAL, MANAGING DIRECTOR & CEO
3. DR. V.R.MEHTA, JT. MANAGING DIRECTOR
4. MR.RAMAN K. SOOD, COMPANY SECRETARY
5. MR. ARUN K. SETH, G.M. (F&A) designated as CFO
Mar 31, 2014
1. Leases:
Finance lease, which effectively transfer to the company all the risks
and benefits incidental to ownership of the leased item, are
capitalized at the lower of the fair value and present value of the
minimum lease payments at the inception of the lease term and disclosed
as leased assets. Lease payments are apportioned between the finance
charges and reduction of the lease liability based on the implicit rate
of return. Fi- nance charges are charged as expenses in the profit and
loss account.
2. Accounting policies not specifically referred to are consistent
with generally accepted accounting principles.
3. The Prefrence Shares shall rank for dividends in priority to equity
Shares for time being. These shares shall be entitled to rank in
priority to equity shares as regards repayment of Capital and arrears
of dividend declared, but shall not be entitled to any further
participation in profit or assets of the Company.
4. During the year the company has alloted 4168571 equity shares of
Rs. 2/- each @ a preimum of Rs. 15.50 per share to promoters and
promoter group compines as per the approved CDR Scheme.
5. Term Loan from Banks & Financial Institutions are secured by way of
first pari-passu charge over entire fixed assets of the company,second
pari-passu charge over the entire current assets of the
company,personal guarantee of Directors and by way of pledge of shares
of promoters. Restructured Bill Discounting/Factoring facilities are
secured by way of subservient charge over entire current assets of the
company. Vehicles loans are secured by way of hypothecation of vehicles
financed.
6. The Company has not received any information from its suppliers
regarding regd. under The Micro Small and Medium Enterprises
Development act 2006. Hence, the information required to be given in
accordance with Section 22 of the said act is not ascertainable and not
disclosed.
7. Total Cost of Quoted Investment is Rs. 4005.53lacs(Market Value
Rs.3671.64 lacs) and Unquoted Investment is Rs. 513.35 lacs
8. The shares of Ind Swift Laboratories Ltd are pledged to Banks as
per the sanctioned Corporate Debts Restructuring Scheme of Ind Swift
Laboratories Ltd.
9. Ind Swift Laboratories Ltd, Essix Biosciences Ltd, Fortune India
Construction Ltd and Mansa Print & Publishers Pvt. Ltd are Associates.
10. Fixed Deposits with banks are Rs. 225.73 lacs (P/Y Rs. 949.24
lacs) out of which Rs.225.53 lacs (P/Y Rs. 948.11 lacs) are Pledged as
'' margin money with banks.
11. Balance with Banks includes Balance on account of unpaid dividend
of Rs. 17.56 lacs (P/Y Rs. 20.82 lacs)
12. During the period the Company has Transferred a sum of Rs. 3.26
lacs to Investor Education and Protection Fund on account of Unclaimed
dividend for Financial Year 2005-06 (P/Y Rs. 3.24 lacs)
13. In the opinion of the Board, the current assets,loans & advances
shown in the Balance Sheet have a value of realization in the ordinary
course of business at least equal to the amount at which they are
stated in the balance sheet and provision for all known and determined
liabilities is adequate.
14. Expenses includes Rs. 36.96 lacs (P/Y Rs. 32.08 lacs) as expenses
relating to previous years.
15. In view of losses, the managerial remuneration paid/provided is in
excess of limit prescribed main schedule XIV of Companies Act 1956.
However Company is in process of obtaining the approval from Central
Government in this regard.
During the year, the Company has undertaken a review of all fixed
assets in line with the requirement of AS-28 on "Impairment of
16. Assets" issued by the Institute of Chartered Accountants of India.
Based on such review, no provision for impairment is required to be
recognized for the year.
17. The previous year figures have been re-arranged and re-grouped
wherever found necessary.
18. Contingent liabilities outstanding as on 31.03.2014 are as under:
a) Foreign Letter of Credit/Inland Letter of Credit/Bank Guarantee
issued by Bankers:
(Rs.in Lacs)
Particulars 2013-14 2012-13
FLC /ILC 1630.91 2310.91
BG 18.06 822.69
b) Arrears of Cumulative Dividend on cumulative Redeemable Preference
Shares amounting to Rs. 42.60 Lacs Previous year (28.40Lacs).
c) In respect of Income Tax matters pending before appellate
authorities/CIT (Appeals) which the Company expects to succeed, based
on decisions of Tribunals/Courts. There is contingent liability
amounting to Rs. 578 Lacs.
d) In respect of Sale Tax matters pending before appellate
authorities/CIT (Appeals) which the Company expects to succeed, based
on decisions of Tribunals/Courts. There is contingent liability
amounting to Rs. 590.64 Lacs.
19. During the year, the Company has received a sum of Rs. 668.10 Lacs
as promoters contributions towards Share Application Money in
compliance with the term and conditions of CDR Package.
10. R & D: Company is consistently undertaking Research & Development
in new areas of Medicine. The R & D facility of the company is duly
recognized by Deptt. of Science & Technology, Govt. of India. Company''s
team consisting of highly qualified scientists has proven their
expertise in various areas of technology development. Expenses on
Research phase are charged to Profit and Loss account and
11. The debts of the company including interest have been restructured
by the corporate debt restructuring cell w.e.f 01.07.2012 under the
aegis of Corporate Debt Restructuring Scheme. As per the approved
scheme, restructured debts are now repayable over a pe- riod of eight
and half years including moratorium period of 1-2years. The Debt
Restructuring Scheme is not approved by Non CDR member Tata Capital
Financial Services Ltd. However effect of Reschedulment of loan has
been incorporated in Balance Sheet as per corporate debt restructuring
scheme except in case of Tata Capital Financial Services Ltd which has
been taken as per their original sanctioned letter.
12. The fixed deposits of the company has been restructured by the
Company Law Board vide its order dated 30.09.2013 in view of petition
CP No, 27.02.2013 filed by the company. As per the scheme approved by
the Company Law Board the fixed deposits are now repayable over a
period of one to five years from the date of maturity. The effect of
reschedulement of fixed deposits has been incorporated in Balance Sheet
as per the approved scheme.
13. During the year some banks have not charged interest for full year
due to sub standard account on cash credit, working capital Term Loan,
Term Loan and Funded interest Term Loan accounts. The accrued liability
on account of the same amounting to Rs. 3709.75 lacs has not been
provided in books of accounts.
14. Remittance in Foreign Currency on Account of Dividend:
The Company has paid dividend in respect of shares held by
Non-Residents. Where the amount is also credited to Non-Resident
External Account.
15. The current accounting period is for Twelve months from 01.04.2013
to 31.03.2014 and previous accounting period was for nine months from
01.07.2012 to 31.03.2013, hence the figures for the current period are
not comparable with the previous period.
Mar 31, 2013
1. The Prefrence Shares shall rank for dividends in priority to equity
Shares for time being. These shares shall be entitled to rank in
priority to equity shares as regards repayment of Capital and arrears
of dividend declared, but shall not be entitled to any further
participation in profit or assets of the Company
2. Term Loan from Banks & Financial Institutions are secured by way of
first pari-passu charge over entire fixed assets of the company,second
pari-passu charge over the entire current assets of the
company,personal guarantee of Directors and by way of pledge of shares
of promoters. Restructured Bill Discounting/Factoring facilities
aresecured by way of subservient charge over entire current assets of
the company. Vehicles loans are secured byway of hypothecation of
vehicles financed.
3. Fixed Deposits with banks are Rs. 949.24 lacs (P/Y Rs. 1976.93
lacs) out of which Rs.948.11 lacs (P/Y Rs. 1758.42 lacs)
are Pledged as margin money with banks.
4. Balance with Banks includes Balance on account of unpaid dividend
of Rs. 20.82 lacs(P/Y Rs. 24.16lacs)
5. During the period the Company has transferred a sum of Rs. 3.24 lacs
to Investor Education and Protection Fund on account of Unclaimed
dividend for Financial Year 2004-05 (P/Y Rs. 2.65 lacs)
6. In the opinion of the Board, the current assets,loans & advances
shown in the Balance Sheet have a value of realization in the ordinary
course of business at least equal to the amount at which they are stated
in the balance sheet and provision for all known and determined
liabilities is adequate.
7. Expenses includes Rs. 32.08Lacs (P/Y Rs. 18.29Lacs) as expenses
relating to previous years.
8. In view of losses, the managerial remuneration paid/provided is in
excess of limit prescribed under schedule XIV of Companies Act 1956.
However Company is in process of obtaining the approval from Central
Government in this regard. During the year, the Company has undertaken
a review of all fixed assets in line with the requirement of AS-28 on
"Impairment of Assets" issued by the Institute of Chartered Accountants
of India. Based on such review, no provision for impairment is required
to be recognized for the year.
9. The previous year figures have been re-arranged and re-grouped
wherever found necessary.
10. Contingent liabilities outstanding as on 31.03.2013 are as under:
a) Foreign Letter of Credit/Inland Letter of Credit/Bank Guarantee
issued by Bankers:
(Rs.in Lacs)
Particulars 2012-13 2011-12
FLC /ILC 2310.91 21427.49
BG 822.69 1404.25
b) Arrears of Cumulative Dividend on cumulative Redeemable Preference
Shares amounting to Rs.28.40 Lacs Previous year (14.20Lacs).
c) In respect of Income Tax matters pending before appellate
authorities/CIT (Appeals) which the Company expects to succeed, based
on decisions of Tribunals/Courts. There is contingent liability
amounting to Rs. 578 Lacs.
d) In respect of Sale Tax matters pending before appellate
authorities/CIT (Appeals) which the Company expects to succeed, based
on decisions of Tribunals/Courts. There is contingent liability
amounting to Rs. 590.64 Lacs.
11. During the period, the Company has received a sum of Rs. 729.50
Lacs as promoters contributions towards Share Application Money in
compliance with the term and conditions of CDR Package.
12. Segment Reporting
Primary Segment (Business Segments)
The Company operates mainly in the business segment of Pharmaceutical
Products, and in the opinion of the management the inherent nature of
activities in which it is engaged are governed by the same set of risks
and reward. The company has also diversified into Dairy segment in
addition to the Pharmaceuticals. As the revenue from the dairy segment
is less than 10% of total income of the company, hence separate segment
reporting has not been given.
13. The debts of the company including interest have been restructured
by the corporate debt restructuring cell w.e.f 01.07.2012 under the
aegis of Corporate Debt Restructuring Scheme. As per the approved
scheme, restructured debts are now repayable over a period of eight and
half years including moratorium period of 1-2years. The Debt
Restructuring Scheme is pending for approval from Non CDR members IFCI
and Tata Capital Financial Services Ltd, however effect of
Reschedulment of loan has been incorporated in Balance Sheet as per
corporate debt restructuring scheme subject to their approval.
14. Remittance in Foreign Currency on Account of Dividend:
The Company has paid dividend in respect of shares held by
Non-Residents. Where the amount is also credited to Non-Resident
External Account.
15. Related Party Disclosure
(a) List of related parties & their relationship - As per annexure- 'A'
(b) Related party transactions. - As per annexure- 'B'
16. The current accounting period is for nine months from 01.07.2012 to
31.03.2013 and previous accounting period was for fifteen months from
01.04.2011 to 30.06.2012, hence the figures for the current period are
not comparable with the previous period
RELATED PARTY DISCLOSURES
LIST OF RELATED PARTIES AND RELATIONSHIPS
S.NO. RELATIONSHIP NAME OF PARTY
(A) ASSOCIATES 1. ESSIX BIOSCIENCES LTD.
2. IND SWIFT LABORATORIES LIMITED
3. MANSA PRINT & PUBLISHERS LTD.
4. FORTUNE INDIA CONSTRUCTION LTD
5. DASHMESH MEDICARE PVT LTD.
6. 3M ADVERTISING & PUBLISHERS LTD
7. SWIFT FUNDAMENTAL RESEARCH &
EDUCATION SOCIETY
(B) KEY MANAGEMENT PERSONNEL 1. MR. S.R. MEHTA
- DIRECTORS 2. DR. G. MUNJAL
3. DR. V.R.MEHTA
Mar 31, 2011
1. The previous year fgures have been re-arranged and re-grouped
wherever necessary.
2. The Company has sent letter of balance confirmation to all the
parties but only a few have responded so far. So the balance in the
party accounts whether in debit or in credit are subject to
reconciliation.
3. The Company is a manufacturing company, so the information pursuant
to the provisions of paragraph 3 & 4 of part II of schedule VI to the
Companies Act, 1956 is as under: -
a) (i) Licensed Capacity - N.A.
(ii) Installed Capacity - (As on 31.03.2011)
- (As certified by the Management)
b) Particulars of actual production, sales & closing stock of fnished
goods - As per annexure - I
c) Particulars of consumption of Material- As per annexure - II
4. Fixed deposits with banks are Rs.142534887/- (P/Y Rs.179826452/-)
out of which Rs. 116208122/- (P/Y- Rs.90825353/-) are pledged as margin
money with banks.
5. Expenses includes Rs.1828674/- (P/Y Rs.875994/-) as expenses
relating to previous years.
6. Depreciation on assets has been provided for the entire accounting
year on straight line method at the rates prescribed by Schedule XIV of
the Companies Act, 1956. Depreciation in respect of additions to assets
has been charged on prorata basis with reference to the period of use
of such assets.
7. Contingent liabilities outstanding as on 31.03.2011 are as under:
a) Foreign Letter of Credit/Inland Letter of Credit/Bank Guarantee
issued by Bankers:
(Rs.in Lacs)
Particulars 2010-11 2009-10
FLC 2221.77 679.00
ILC 17777.04 11762.58
BG 140.40 96.89
b) Corporate Guarantee on behalf of Ind Swift Laboratories Ltd of which
company is the shareholder amounting to Rs. 3749 Lacs (Previous Year
Rs.5000 Lacs) based on outstanding balances at the year end.
c) In respect of Income Tax matters pending before appellate
authorities/CIT (Appeals) which the Company expects to succeed, based
on decisions of Tribunals/Courts. There is contingent liability
amounting to Rs. 5.78 crores.
8. Miscellaneous Income of Rs. 15,85,34,600/- is on account of surplus
as difference of price on cancellation of contracts due to non supply
of CMO by various parties during the year and on account of any
possible error in the records. The said surplus has been accounted for
on the basis of disclosure of income made by the company during action
u/s 132 of the Income Tax Act ,1961.
9. Sales fgures for Chandigarh Depot are not reconcilied with Sales
Tax Returns in the absence of sales tax records which was lying with
sale tax deptt. at the time of compilation of Balance Sheet.
10. During the year the company was allotted 30,00,000 equity shares
of Ind Swift Laboratories Ltd, the promoters Group company on
conversion of 30,00,000 Zero Coupon convertible warrants.
11. a) During the year the company has allotted 1420000 cumulative
Redeemable Preference Shares of Rs. 100/- each amounting to Rs.14.20
Crores against advance Share Capital money received.
b) During the year the Company has allotted 8000000 zero coupon
convertible warrants to promoters group companies and other body
corporate out of which 1000000 zero coupon convertible warrants have
been converted in 1000000 equity shares of the company of Rs. 2/-each
at a premium of Rs. 38/- per share.
c) During the year 4000000 zero coupon convertible Warrants issued by
the company to M/s Essix Bioscinces Ltd have been converted in equity
shares of Rs. 2/-each at a premium of Rs. 23/- each.
12. The company has introduced new product ranges like Inorine M,
Menoguard MF, Aclovir 800(AD), Telhim, Arnold Combipack, Bodyfit, NEO
Quadrimix (AD), Televo-OZ etc. during the year 2010-2011. The company
has also substantially increased the number of head quarters in the
states where it was working on a smaller scale. Expenses relating to
the introduction & establishment of New Products Head Quarters have
enduring beneficial effect beyond the year in which these are incurred.
Such expenses are clubbed under the head Seed Marketing Expenses to be
amortized in subsequent five equal annual installments.
13. R & D: Company is consistently undertaking Research & Development
in new areas of Medicine. The R & D facility of the company is duly
recognized by Deptt. of Science & Technology, Govt. of India. Company's
team consisting of highly qualified scientists has proven their
expertise in various areas of technology development. Expenses on
Research phase are charged to Profit and Loss account and Expenses
relating to development phase shall be capitalised in subsequent years
in accordance with AS-26. Expenditure on R&D incurred by the Company
during the Year is:
14. Total amount of term loans/installments of term loans repayable
during twelve months following 31.03.2011 is Rs 8049.28 Lacs (Previous
year Rs.5964.71 Lacs).
15. Loans and Advances due from officers of the company is Rs. Nil
(Previous Year Rs.Nil)
16. In the opinion of the Board, the current assets, loans & advances
shown in the Balance Sheet have a value of realization in the ordinary
course of business at least equal to the amount at which they are
stated in the balance sheet and provision for all known and determined
liabilities is adequate.
17. The Company has not received any information from its suppliers
regarding registered under "The Micro Small and Medium Enterprises
Development act 2006". Hence, the information required to be given in
accordance in this section 22 of the said act is not ascertainable and
not disclosed.
18. There were no lease obligations outstanding during the year and
consequently no lease rentals were payable. There are no unexpired
lease obligations as at the year end.
19. In the opinion of the management, the company is mainly engaged in
the business of Pharmaceuticals. All activities of the company revolve
around the main business and as such there are no separate reportable
segments. The company caters mainly to the needs of the domestic
market. The export turnover being less than 10% of the total turnover,
there are no reportable geographical segments.
20. Company has taken a Defned Contribution Plan from Life Insurance
Corporation of India which takes care its liability towards Gratuity
entirely. As per Accounting Standard 15 on "Employee Benefits" the
disclosure is given below.
i) Employer's Contribution to PF Rs .12046525/-
ii) Contribution to Gratuity Rs. 3593962/-
21. Intangible Assets :
a) Product Technology acquired by the company is recognized as an
intangible asset and is amortised over its useful life of 5 years.
b) Product Technology addition forming Part of Depreciation schedule
consists of following:
(Rs. in Lacs) Addition during the year 410.08
21 Related Party Disclosure
(a) List of related parties & their relationship à As per annexure- 'A'
(b) Related party transactions. Ã As per annexure- 'B'
22 During the year, the Company has undertaken a review of all fixed
assets in line with the requirement of AS- 28 on "Impairment of Assets"
issued by the Institute of Chartered Accountants of India. Based on
such review, no provision for impairment is required to be recognized
for the year.
23 The fgures have been rounded to the nearest rupee.
Mar 31, 2010
1. The previous year figures have been re-arranged and re-grouped
wherever necessary.
2. The Company has sent letter of balance confirmation to all the
parties but only a few have re- sponded so far. So the balance in the
party accounts whether in debit or in credit are subject to
reconciliation.
3. Land Amounting to Rs. 4.43Lacs continues to be in the name of Mukur
Pharmaceutical Co. Pvt. Ltd.
4. The Company is a manufacturing company, so the information pursuant
to the provisions of paragraph 3 & 4 of part II of schedule VI to the
Companies Act, 1956 is as under: -
a) (i) Licensed Capacity - N.A.
(ii) Installed Capacity - (As on 31.03.2010)
- (As certified by the Management)
5. Fixed deposits with banks are Rs. 179826452/- (P/Y Rs.81988543/-)
out of which Rs.90825353/- ( P/Y- Rs.62444895/-) are pledged as margin
money with banks.
6. Expenses includes Rs.875994/- (P/Y Rs.3038831/-) as expenses
relating to previous years.
7 . Income includes Rs.Nil (P/Y Rs.999118/-) as income relating to
previous years.
8. Depreciation on assets has been provided for the entire accounting
year on straight line method at the rates prescribed by Schedule XIV of
the Companies Act, 1956. Depreciation in respect of additions to assets
has been charged on prorata basis with reference to the period of use
of such assets.
9. Contingent liabilities outstanding as on 31.03.2010 are as under:
a) Foreign Letter of Credit/Inland Letter of Credit/Bank Guarantee
issued by Bankers:
Particulars 2009-10 2008-09
(Rs.in Lacs)
FLC 679.00 351.39
ILC 11762.58 9055.31
BG 96.89 68.19
b) Corporate Guarantee on behalf of Ind Swift Laboratories Ltd of which
company is the share- holder amounting to Rs.5000/- Lacs ( Previous
Year Rs.1752/- Lacs) based on outstanding balances at the year end.
c) In respect of Income Tax matters pending before appellate
authorities/CIT (Appeals) which the Company expects to succeed, based
on decisions of Tribunals/Courts. There is contingent liability
amounting to Rs. 5.56 crores.
10. Company has further invested Rs. 37500000/- in M/s Ind Swift Labs
Ltd for which 30,00,000 of Zero coupon optionally convertible warrants
from the Promoters Group Company have been received.
11. a) The Company has raised a sum of Rs. 24.20 Crores only (Twenty
Four Crores twenty lacs only) as advance against Share Capital from
private corporate Bodies, for which the company is in pro- cess of
issuing Preference Shares.
b) The Company has received a sum of Rs. 2.5 crores (Rs. Two Crores
Five lacs only) from M/s Essix Biosciences Ltd. as application money
(25% of the issue price) for issue of 4000000 Zero Coupon Convertible
Warrants (ZCCB) issued for Rs. 25/- per warrant.
12. The Investment in M/s Mansa Print & Publishers Ltd as on 31.03.2010
is Rs.1334500/-.
13. The company has introduced new product ranges like Anich-3,Clarie
Dry Syrup,Cirrholiv Dry Syrup, PM Care Gold, Expodox-CV 100,
Glypar-lmg, Glypar M1ER, Glypar 2mg etc. during the year 2009-2010. The
company has also substantially increased the number of head quarters in
the states where it was working on a smaller scale. Expenses relating
to the introduction & establish- ment of New Products Head Quarters
have enduring beneficial effect beyond the year in which these are
incurred. Such expenses are clubbed under the head Seed Marketing
Expenses to be amortized in subsequent five equal annual installments.
The Depreciation and Misc. exp. w/off related to Research & development
are clubbed under respective heads in profit & loss account.
14. Total amount of term loans/installments of term loans repayable
during twelve months following 31.03.2010 is Rs 5964.71 Lacs (Previous
year Rs.4738.42 Lacs) and public deposits amounting to Rs. 482.50 Lacs
(P/Y Rs.789.25 Lacs).
15. Loans and Advances due from officers of the company is Rs.3.72Lacs
(Previous Year Rs.5.51Lacs) Maximum amount outstanding during the year
was Rs.5.82 Lacs (Previous Year Rs.7.24 Lacs).
16. In the opinion of the Board, the current assets, loans & advances
shown in the Balance Sheet have a value of realization in the ordinary
course of business at least equal to the amount at which they are
stated in the balance sheet and provision for all known and determined
liabilities is adequate.
17. Some of the suppliers of materials have been identified as Small
Scale Industrial Undertakings on the basis of the information available
with the company. However some of these parties has an outstanding
credit balance for more than 30days as on 31.03.2010
18. There were no lease obligations outstanding during the year and
consequently no lease rentals were payable. There are no unexpired
lease obligations as at the year end.
19. In the opinion of the management, the company is mainly engaged in
the business of Pharma- ceuticals. All activities of the company
revolve around the fnain business and as such there are no separate
reportable segments. The company caters mainly to the needs of the
domestic market. The export turnover being less than 10% of the total
turnover, there are no reportable geographi- cal segments.
20. Due to occurrence of fire at Parwanoo Plant there was loss of
stocks and assets thus the company has lodged an insurance claim of Rs.
7.11 Crores with united India Assurance Company Ltd. and the same is
pending as on 31.03.2010
21. Company has taken a Defined Contribution Plan from Life Insurance
Corporation of India which takes care its liability towards Gratuity
entirely. As per Accounting Standard 15 on "Employee Benefits the
disclosure is given below.
i) Employers Contribution to PF Rs. 11361502/-
ii) Contribution to Gratuity Rs. 3107710/-
22. Intangible Assets :
a) Product Technology acquired by the company is recognized as an
intangible asset and is amortised over its useful life of 5 years.
23. During the year, the Company has undertaken a review of all fixed
assets in line with the require- ment of AS-28 on "Impairment of
Assets" issued by the Institute of Chartered Accountants of India.
Based on such review, no provision for impairment is required to be
recognized for the year.
24. The figures have been rounded to the nearest rupee.